Pediatric Hodgkin Lymphoma, Version 3.2021
Jamie E. Flerlage, Susan M. Hiniker, Saro H. Armenian, Ellen C. Benya, Adam J. Bobbey, Vivian Y. Chang, Stacy Cooper, Donald W. Coulter, Branko Cuglievan, Bradford S. Hoppe, Leidy Isenalumhe, Kara M. Kelly, Leslie S. Kersun, Adam J. Lamble, Nicole Larrier, J.Fergall Magee, Kwadwo A. Oduro, Martha Pacheco, Anita P. Price, Kenneth B. Roberts, Christine M. Smith, Aliyah R. Sohani, Erin Trovillion, Emily Walling, Ana C. Xavier, Jennifer L. Burns, Mallory Campbell
Abstract
Hodgkin lymphoma (HL) is a highly curable form of cancer, and current treatment regimens are focused on improving treatment efficacy while decreasing the risk of late effects of treatment. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric HL provide recommendations on the workup, diagnostic evaluation, and treatment of classic HL, including principles of pathology, imaging, staging, systemic therapy, and radiation therapy. This portion of the NCCN Guidelines focuses on the management of pediatric classic HL in the upfront and relapsed/refractory settings.